Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Ferric Carboxymaltose in Iron Deficiency Anaemia
NCT06080555Phase 1Completed
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Maximum Serum Concentration (Total Iron), Area Under the Curve from time 0 to last measurable concentration (Total Iron) and 2 more. Started Oct 2023; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT06080555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06080555.